Knobias Clip Report (11-12-2008) AEZS
Submitted By Knobias ClipReport
AEZS: Sale of Rights for Cetrotide(R) to Cowen Healthcare
By Fain Hughes, fhughes@knobias.com
AEterna Zentaris Inc. (AEZS) has signed a definitive agreement to sell to Cowen Healthcare Royalty Partners, L.P. (”CHRP”) its rights to royalties on future sales of Cetrotide(R) covered by its license agreement with Merck Serono. The license agreement between AEterna Zentaris and Merck Serono was signed in 2000 and granted Merck Serono exclusive rights to market, distribute and sell Cetrotide(R) worldwide, with the exception of Japan, in the field of in vitro fertilization. On closing, AEterna Zentaris will receive $52.5 million from CHRP. In addition, contingent on 2010 net sales of Cetrotide(R) reaching a specified level, AEterna Zentaris would receive an additional payment of $2.5 million from CHRP.
Under the terms of the agreement, if cetrorelix, which is currently in Phase 3 clinical trials for the treatment of benign prostatic hyperplasia, is approved for sale by European regulatory authorities in an indication other than in vitro fertilization, AEterna Zentaris has agreed to make a one-time cash payment to CHRP in an amount ranging from $5 million up to a maximum of $15 million. The amount which would be due to CHRP will be higher the earlier the product receives European regulatory approval.
Visit 1800blogger to see all of our industry leading blogs.
November 13th, 2008 at 12:14 pm
IBVR
Let me know what you think. I think its a great company and should be $4+ in a week or so. Here is some info on them.
IBVR
The market has stopped lending for quite some time, due to the excessive leverage and loose lending standards (among other things). The LIBOR rates which are the rates at which the banks lend money to each other is through the roof. This has made it especially hard for small business owners that cannot get money stock their selves, buy advertising or just grow their business is general.
I have been looking around for a company that is actually still lending and I may have found one. IBVR is a relatively new company with light volume, but one that already has done several deals for start up to small companies. IBVR’s Business Model allows smaller non - accredited Investors this option to invest in small public deals or start up companies. with as little as $ 2,500. IBVR caters to the masses, which is very important especially in this day and age.
This business model has allowed IBVR to grow by over 200% in 2008 and fund over 7 million dollars in new deals alone. They expect to continue this growth based on their long term strategy, which should be able to weather any market condition.
With many smaller investors or investment clubs looking outside the conventional stock market investments, IBVR could provide a secure choice for these types of investors.